AtaiBeckley Inc. (ATAI) Stock Analysis
Falling Knife setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $3.85: Quality below floor (1.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 3.5/10. Specifically: Elevated put/call ratio: 1.33; Below-average business quality; Negative price momentum.
AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of... Read more
Sell if holding. Engine safety override at $3.85: Quality below floor (1.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 3.5/10. Specifically: Elevated put/call ratio: 1.33; Below-average business quality; Negative price momentum. Chart setup: Death cross, below all MAs, RSI 39, MACD bearish. Score 3.5/10, high confidence.
Passes 6/8 gates (clean insider activity, no SEC red flags, news events none recent, earnings proximity 58d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.
Recent developments
updated 2026-06-15Recent Developments — AtaiBeckley Inc.
Latest news
- NEWS HC Wainwright & Co. Reiterates Buy on AtaiBeckley, Maintains $25 Price Target — benzinga Jun 8, 2026 positive
- NEWS AtaiBeckley Q1 EPS $(0.08) Beats $(0.11) Estimate, Sales $954.000K Beat $11.111K Estimate — benzinga May 12, 2026 positive
- NEWS 'Health Officials Close To U.S. Secretary Kennedy Explored Ban Of Some Widely Used Antidepressants' - Reuters Exclusive — benzinga May 8, 2026 negative
- NEWS 10 Health Care Stocks With Whale Alerts In Today's Session — benzinga May 1, 2026 neutral
- NEWS FDA Accelerates Action on Treatments for Serious Mental Illness Following Executive Order — benzinga Apr 24, 2026 positive
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
5 floor-breakers
Revenue shrinking — -38.7% YoY. Growth thesis broken unless recovery story develops.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $3.85: Quality below floor (1.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 3.5/10. Specifically: Elevated put/call ratio: 1.33; Below-average business quality; Negative price momentum. Chart setup: Death cross, below all MAs, RSI 39, MACD bearish. Prior stop was $3.59. Score 3.5/10, high confidence.
Take-profit target: $4.90 (+27.1% upside). Prior stop was $3.59. Stop-loss: $3.59.
DATA_ISSUE: analyst_target_implausible (raw $14.00 vs price $3.85 — ratio 3.6×). Rejected, falling back to technical TP.; Quality below floor (1.4 < 4.0); Value-trap signals (2/5): Margin compression (op margin -11.5%), High leverage (D/E 33.0).
AtaiBeckley Inc. trades at a P/E of N/A (forward -8.6). TrendMatrix value score: 5.0/10. Verdict: Sell.
20 analysts cover ATAI with a consensus score of 4.2/5. Average price target: $14.
What does AtaiBeckley Inc. do?AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and...
AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator in Phase 2b trial for cognitive impairment associated with schizophrenia; and ELE-101, a serotonergic psychedelic for the treatment of major depressive disorder. It is also developing VLS-01, an oral transmucosal film formulation of N,N-Dimethyltryptamine in Phase 2 clinical study to treat TRD; EMP-01, an oral formulation of R-3,4-methylenedioxy-methamphetamine that is in Phase 2 clinical study for social anxiety disorder; and EGX-A & EGX-B, which are non-hallucinogenic 5-HT2A receptor agonists for TRD. In addition, the company offers COMP360 for psilocybin therapy; and GRX-917 for the treatment of anxiety, depression, and various neurological disorders. The company was formerly known as Atai Beckley N.V. and changed its name to AtaiBeckley Inc. in December 2025. AtaiBeckley Inc. was founded in 2018 and is based in New York, New York.